MRPI.US Mera Pharmaceuticals Inc
- Market cap
- USD 55.7K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2021.
Is MRPI.US undervalued?
Graham numberThe Graham number of Mera Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mera Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Mera Pharmaceuticals Inc yet.
Mera Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mera Pharmaceuticals Inc
Mera Pharmaceuticals, Inc. focuses on the development and commercialization of natural products from microalgae using its proprietary and large-scale photobioreactor technology. The company is also involved in the development of sea salt; and operation of family entertainment center focused on promoting health and wellness through the Villari's system of martial arts. In addition, it provides food production and delivery services. Mera Pharmaceuticals, Inc. was founded in 19…
Full company profileMera Pharmaceuticals Inc financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mera Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2019 | 2020 | 2021 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 910K | 388K | 387K | 470K | 610K | 599K | 289K | 303K | - | - | 0.00 |
| Gross Profit | 910K | -262K | 92.2K | 198K | 571K | 571K | 243K | 286K | - | - | 0.00 |
| Operating Income | -1.36M | -1.31M | -518K | -331K | -1.98M | -222K | -552K | -201K | - | -5.58 | -5.46K |
| EBITDA | 242K | -276K | -224K | -58.3K | -1.75M | -134K | -524K | -188K | - | - | -5.46K |
| Net Income | -1.10M | -1.31M | -508K | -322K | -1.95M | -193K | -538K | -188K | - | -5.58 | -5.46K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 3.28M | 2.61M | 2.43M | 2.23M | 395K | 257K | 73.4K | 70.7K | - | - | 0.00 |
| Total Liabilities | 337K | 379K | 438K | 412K | 341K | 397K | 750K | 935K | - | 29.76 | 38.6K |
| Shareholders' Equity | 2.94M | 2.24M | 2.00M | 1.81M | 53.8K | -139K | -677K | -865K | - | -29.76 | -38.6K |
| Cash & Short-term Investments | 4.40K | 539.00 | 6.56K | 12.7K | 53.7K | 3.14K | 5.94K | 4.32K | - | - | 0.00 |
| Total Debt | 61.9K | 77.3K | 65.3K | 65.3K | 51.9K | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.25M | -567K | -203K | -44.3K | -119K | -26.5K | 8.56K | -71.8K | - | - | - |
| Capital Expenditure | 14.6K | 3.00 | 29.3K | 9.53K | 1.00 | 24.1K | 150K | 2.29K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.26M | -567K | -232K | -53.9K | -119K | -50.6K | -141K | -74.1K | - | - | - |
| Ratios | |||||||||||
| ROE | -37.6% | -58.4% | -25.5% | -17.8% | -3,617.5% | - | - | - | - | - | - |
| ROA | -33.7% | -49.9% | -20.9% | -14.5% | -492.9% | -74.9% | -733.2% | -265.5% | - | - | - |
| Net Profit Margin | -121.4% | -336.5% | -131.5% | -68.5% | -318.9% | -32.2% | -186.2% | -62.0% | - | - | - |
| Debt to Equity | 0.02x | 0.03x | 0.03x | 0.04x | 0.97x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mera Pharmaceuticals Inc dividends
Mera Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Mera Pharmaceuticals Inc
Ownership data of Mera Pharmaceuticals Inc is not available yet.
Mera Pharmaceuticals Inc company profile
- Company name
- Mera Pharmaceuticals Inc
- Ticker
- MRPI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- October
- Address
- 8275 S. Easter Avenue, Las Vegas, NV, United States, 89123
- Phone
- 604 500 4157
- Website
- merapharma.com
About Mera Pharmaceuticals Inc
Mera Pharmaceuticals, Inc. focuses on the development and commercialization of natural products from microalgae using its proprietary and large-scale photobioreactor technology. The company is also involved in the development of sea salt; and operation of family entertainment center focused on promoting health and wellness through the Villari's system of martial arts. In addition, it provides food production and delivery services. Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Las Vegas, Nevada.
Mera Pharmaceuticals Inc management
5- Mr. Benny DoroCEO, Interim Director, President & Secretary · born 1968
- Mr. Lawrence Harris WolfeChief Financial Officer, Vice President of Finance and Director · born 1963
- Ms. Melanie K. KelekolioGeneral Manager of The Operations & Production Facility and Vice President · born 1968
- Ms. Joyce MarkleySecretary and Director · born 1952
- Mr. Rafi MarkariansTreasurer & Director · born 1966